{"id":970073,"date":"2026-06-03T08:36:10","date_gmt":"2026-06-03T12:36:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/"},"modified":"2026-06-03T08:36:10","modified_gmt":"2026-06-03T12:36:10","slug":"liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/","title":{"rendered":"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds"},"content":{"rendered":"<div class=\"mw_release\">\n<p>FULLERTON, Calif., June  03, 2026  (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d) today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000\u00a0shares of common stock of the Company (the \u201cExisting Warrants\u201d). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000\u00a0million shares of common stock (the \u201cNew Warrants\u201d). In connection with the exercise, the Company also agreed to reduce the exercise price of the Existing Warrants to $0.18.<\/p>\n<p>The proceeds to the Company from the exercise of the existing warrants are $1.9 million, prior to deducting fees to the financial advisor and estimated expenses.<\/p>\n<p>Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction.<\/p>\n<p>The New Warrants each have an exercise price of $0.18 per underlying share and are not exercisable until the Company obtains stockholder approval in accordance with Nasdaq rules. The New Warrants will expire five years from the date such stockholder approval is obtained.<\/p>\n<p>The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the New Warrants.<\/p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>\n        <strong>About Liminatus Pharma, Inc. (Nasdaq: LIMN)<\/strong><br \/>\n        \n      <\/p>\n<p>Liminatus Pharma is a biopharmaceutical company focused on the development of innovative therapies for oncology and other serious diseases.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        \n      <\/p>\n<p>Liminatus Pharma, Inc.:<\/p>\n<p>Chris Kim, CEO \u2014 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CMnZp6iZQXv23ERQx0FllJhpGnt2t6YnZBvQYKh4cIgr-hG-GAssdtZ0hNL2TVG0DoZYHx-JvN-l2nkf7F0El2DkD8FL9UdP7wG4LghIpdzH5TWrfpZjBaPGzEbkUgZs\" rel=\"nofollow\" target=\"_blank\">info@liminatuspharma.com<\/a>, (213) 273-5453<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements made in this press release are forward-looking statements within the meaning of applicable securities laws. When used in this press release, the words \u201cestimates,\u201d \u201cprojected,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cforecasts,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cfuture,\u201d \u201cpropose\u201d and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company\u2019s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: the ability to satisfy the closing conditions related to the warrant exercise transaction and the overall timing and completion of such closing, the intended use of the net proceeds from the warrant exercise transaction and the exercise of the new warrants prior to their expiration; the risk that the approval of the stockholders of the Company is not obtained; the Company\u2019s need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; performance of the Company\u2019s business; risks relating to the Company\u2019s sources of cash and cash resources; risks relating to the Company\u2019s ability to manage future growth; the effects of competition on the Company\u2019s future business; the Company\u2019s ability to maintain compliance with the Nasdaq continued listing requirements in order to prevent its common stock from being delisted; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries involving the Company; the impact of pandemics, global conflicts, the global economic status or tariffs on the Company\u2019s business; and those factors discussed in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on March 31, 2026, and other documents of the Company filed, or to be filed, with the SEC. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWY3ZGVmZTctMzU4Ni00NjRkLTg3MDgtZWRjODgyYmY3MjVkLTEzMTU0NzUtMjAyNi0wNi0wMy1lbg==\/tiny\/Liminatus-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d) today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000\u00a0shares of common stock of the Company (the \u201cExisting Warrants\u201d). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000\u00a0million shares of common stock (the \u201cNew Warrants\u201d). In connection with the exercise, the Company also agreed to reduce the exercise price of the Existing Warrants to $0.18. The proceeds to the Company from the exercise of the existing warrants are $1.9 million, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970073","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d) today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000\u00a0shares of common stock of the Company (the \u201cExisting Warrants\u201d). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000\u00a0million shares of common stock (the \u201cNew Warrants\u201d). In connection with the exercise, the Company also agreed to reduce the exercise price of the Existing Warrants to $0.18. The proceeds to the Company from the exercise of the existing warrants are $1.9 million, &hellip; Continue reading &quot;Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T12:36:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds\",\"datePublished\":\"2026-06-03T12:36:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/\"},\"wordCount\":774,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/\",\"name\":\"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=\",\"datePublished\":\"2026-06-03T12:36:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/","og_locale":"en_US","og_type":"article","og_title":"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - Market Newsdesk","og_description":"FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d) today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000\u00a0shares of common stock of the Company (the \u201cExisting Warrants\u201d). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000\u00a0million shares of common stock (the \u201cNew Warrants\u201d). In connection with the exercise, the Company also agreed to reduce the exercise price of the Existing Warrants to $0.18. The proceeds to the Company from the exercise of the existing warrants are $1.9 million, &hellip; Continue reading \"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-03T12:36:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds","datePublished":"2026-06-03T12:36:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/"},"wordCount":774,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/","name":"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=","datePublished":"2026-06-03T12:36:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTI2MSM3NjM0ODY3IzIzMDM5MjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-enters-into-warrant-exercise-transaction-for-1-9-million-in-gross-proceeds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970073"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970073\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}